GB1423244A - Dilution agent - Google Patents

Dilution agent

Info

Publication number
GB1423244A
GB1423244A GB4780473A GB4780473A GB1423244A GB 1423244 A GB1423244 A GB 1423244A GB 4780473 A GB4780473 A GB 4780473A GB 4780473 A GB4780473 A GB 4780473A GB 1423244 A GB1423244 A GB 1423244A
Authority
GB
United Kingdom
Prior art keywords
salt
buffer solution
alkali metal
oct
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4780473A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of GB1423244A publication Critical patent/GB1423244A/en
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Abstract

1423244 Buffer solution F HOFFMANNLA ROCHE & CO A G 12 Oct 1973 [13 Oct 1972] 47804/73 Heading G1B An aqueous buffer solution having a pH of about 6À5 comprises per litre a salt of an organic acid with an alkali metal in an amount which is the mole equivalent of about 1À3 gms per litre of the disodium salt of ethylene diamine tetra acetic acid dihydrate, a preservative and an alkali metal hydroxide. The alkali metal of the salt is perferably the same as that of the hydroxide, and is suitably sodium. The salt is preferably the disodium salt of ethylene diamine tetra acetic acid dihydrate. A suitable preservative is sodium azide. There may also be present a proteinaceous material inert to CEA (carcinoembryonic antigen) antibody-antigen reactions, such as bovine serum albumin. The aqueous buffer solution may be prepared by diluting a concentrate of the ingredients with deionized or distilled water. The buffer solution may be used as a substitute for plasma extract in the preparation of antiserum titration curves and standard antigen inhibition curves.
GB4780473A 1972-10-13 1973-10-12 Dilution agent Expired GB1423244A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00297565A US3852415A (en) 1972-10-13 1972-10-13 Compositions for use in radioimmunoassay as a substitute for blood plasma extract in determination of carcinoembryonic antigen

Publications (1)

Publication Number Publication Date
GB1423244A true GB1423244A (en) 1976-02-04

Family

ID=23146844

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4780473A Expired GB1423244A (en) 1972-10-13 1973-10-12 Dilution agent

Country Status (15)

Country Link
US (1) US3852415A (en)
JP (1) JPS5315130B2 (en)
AU (1) AU467511B2 (en)
BE (1) BE805991A (en)
CA (1) CA1012458A (en)
CH (1) CH584409A5 (en)
DD (1) DD108151A5 (en)
DE (1) DE2349738C3 (en)
FR (1) FR2203525A5 (en)
GB (1) GB1423244A (en)
IL (1) IL43378A (en)
IT (1) IT1001584B (en)
NL (1) NL161884C (en)
SE (1) SE417460B (en)
ZA (2) ZA723264B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207633A2 (en) * 1985-06-03 1987-01-07 Erika, Inc. Sterilant compositions

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901870A (en) * 1974-03-12 1975-08-26 Behringwerke Ag Derivative of alpha' 1'-fetospecific serum protein and process for its manufacture
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US3999944A (en) * 1975-02-28 1976-12-28 Hoffmann-La Roche Inc. Detection of breast cancer
US4043757A (en) * 1975-05-20 1977-08-23 Ortho Pharmaceutical Corporation Method for detection of human mammary carcinoma
US4152410A (en) * 1975-09-03 1979-05-01 Eisai Co., Ltd. Diagnosis reagent for neoplasm and method for diagnosis of neoplasm
US4379839A (en) * 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
JPS562557A (en) * 1979-06-22 1981-01-12 Green Cross Corp:The Aqueous solvent for coagulation test
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
JPS57208459A (en) * 1981-06-19 1982-12-21 Eisai Co Ltd Measuring method using enzyme-labelled antibody and reagent
US4631254A (en) * 1982-12-06 1986-12-23 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4624916A (en) * 1984-04-06 1986-11-25 International Immunoassay Laboratories, Inc. Process and composition for the rapid quantitation of small levels of creative kinase-MB isoenzyme
JPS61280566A (en) * 1984-09-03 1986-12-11 Hiroaki Sawai Direct immunoassay of 2'-5'-oligoadenylic acid
US6013772A (en) * 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
CA1296253C (en) * 1986-10-20 1992-02-25 Praveen Tyle Stabilized growth hormone compositions
US5296377A (en) * 1992-12-15 1994-03-22 Boehringer Mannheim Corporation Control reagent containing a hydroxylamine or an antioxidant
CA2794841C (en) 2010-05-20 2021-02-23 Ecolab Usa Inc. Rheology modified low foaming liquid antimicrobial compositions and methods of use thereof
KR102384708B1 (en) * 2020-06-19 2022-04-11 대한민국 Artificial blood for bloodstain pattern analysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) * 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3697638A (en) * 1970-06-01 1972-10-10 Hoffmann La Roche Antigens

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207633A2 (en) * 1985-06-03 1987-01-07 Erika, Inc. Sterilant compositions
EP0207633A3 (en) * 1985-06-03 1987-05-06 National Medical Care Sterilant compositions
US4690772A (en) * 1985-06-03 1987-09-01 National Medical Care Sterilant compositions

Also Published As

Publication number Publication date
SE417460B (en) 1981-03-16
NL7314093A (en) 1974-04-16
DE2349738A1 (en) 1974-04-18
DD108151A5 (en) 1974-09-05
IL43378A (en) 1976-04-30
AU6124273A (en) 1975-05-01
CA1012458A (en) 1977-06-21
JPS5315130B2 (en) 1978-05-23
BE805991A (en) 1974-04-12
NL161884C (en) 1980-03-17
CH584409A5 (en) 1977-01-31
DE2349738B2 (en) 1978-01-19
FR2203525A5 (en) 1974-05-10
US3852415A (en) 1974-12-03
DE2349738C3 (en) 1981-06-19
ZA737693B (en) 1974-08-28
IL43378A0 (en) 1974-01-14
IT1001584B (en) 1976-04-30
NL161884B (en) 1979-10-15
JPS4971133A (en) 1974-07-10
ZA723264B (en) 1974-08-28
AU467511B2 (en) 1975-12-04

Similar Documents

Publication Publication Date Title
GB1423244A (en) Dilution agent
GB1132474A (en) Method for the preparation of thiogold (i) compounds
ES8504236A1 (en) Enhanced aqueous chemiluminescent systems.
GB1252781A (en) Composition of matter for limiting dehydration and fatigue during periods of physical exertion
FI960327A0 (en) Process for the preparation of aluminum salt solutions
SE8900828D0 (en) ANTIVIRAL AND IMMUNSTIMULATING PHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR PREPARING THEM
GB1384768A (en) Hair bleaching compositions and process
FR2375341A1 (en) CORROSION INHIBITOR FOR ALUMINUM IN ALKALINE SOLUTIONS
GB1442772A (en) Inhibition of leukaemia utilizing 5-methyl-tetrahydrohomofolate
GB1533906A (en) Process for reducing the water sensitivity of polyvinyl alcohol
ES541054A0 (en) A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION INCLUDING AZAPROPANONE
GB748024A (en) Improved therapeutic preparations of iron
AU565084B2 (en) Succinic acid mono-dialkylamides as water-soluble corrosion inhibitors
FR2424919A1 (en) SUBSTITUTE QUINOLEINECARBOXYLIC ACID AND ITS DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
GB1356909A (en) Process for the preparation of succinylosuccinic acid diesters
GB1345495A (en) Standard glycerol solution
GB643268A (en) Improved process for the preparation of prolonged effect insulin products
ZA872877B (en) Stable aqueous solution of vincristine sulfate
IE37143L (en) Citric acid
AU534886B2 (en) Solutions of canrenoic acid and furosemide salts
GB1292832A (en) Developing composition
GB1213154A (en) A process for the solubilization of papaveroline and/or papaveroline tetrabenzoylate
DK157902C (en) HIGH CONCENTRATED Aqueous AMINOXIDE PREPARATIONS AND PROCEDURES FOR PRODUCING THEM
ES2082159T3 (en) HYDRO-SOLUBLE THIOUREA DERIVATIVES AND PROCEDURE FOR ITS PREPARATION.
Owen et al. Na/K/Cl cotransport in cultured human fibroblasts.

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee